All In Biotech

Drug Trial Radar · NCT00441558

A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).

Worldwide One-year Open-label Safety Study of Flibanserin in Women With HSDD

Last checked: Nov 20, 2026Latest source record: Jun 13, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,723

Actual

Start

Feb 2007

Primary completion

Aug 2009

Study completion Aug 2009

Sponsor

Lead sponsor
Sprout Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Mar 1, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine if long-term treatment with Flibanserin is safe and to monitor the effectiveness of Flibanserin in Women with HSDD that have already completed a previous study (511.70/71/.74/.75/.105) with Flibanserin.

Conditions

  • Sexual Dysfunctions, Psychological

Interventions

  • FlibanserinDrug

    flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Frequency of Adverse Events (Side Effects).Time frame: 52 weeks

Locations

196 sites in 2 countries. Site status is shown where the registry gives one.

  • 511.84.01079 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 511.84.01193 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 511.84.01188 Boehringer Ingelheim Investigational Site

    Huntsville, Alabama

  • 511.84.01110 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 511.84.01142 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 511.84.01157 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 511.84.01162 Boehringer Ingelheim Investigational Site

    Little Rock, Alaska

  • 511.84.01070 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 511.84.01191 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 511.84.01115 Boehringer Ingelheim Investigational Site

    Tucson, Arizona

  • 511.84.01013 Boehringer Ingelheim Investigational Site

    Jonesboro, Arkansas

  • 511.84.01087 Boehringer Ingelheim Investigational Site

    Berkeley, California

  • 511.84.01077 Boehringer Ingelheim Investigational Site

    Encinitas, California

  • 511.84.01074 Boehringer Ingelheim Investigational Site

    Fair Oaks, California

  • 511.84.01104 Boehringer Ingelheim Investigational Site

    Irvine, California

  • 511.84.01037 Boehringer Ingelheim Investigational Site

    La Jolla, California

  • 511.84.01056 Boehringer Ingelheim Investigational Site

    Sacramento, California

  • 511.84.01195 Boehringer Ingelheim Investigational Site

    Sacramento, California

  • 511.84.01043 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 511.84.01047 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 511.84.01096 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 511.84.01040 Boehringer Ingelheim Investigational Site

    Stanford, California

  • 511.84.01048 Boehringer Ingelheim Investigational Site

    Tarzana, California

  • 511.84.01017 Boehringer Ingelheim Investigational Site

    Torrance, California

  • 511.84.01173 Boehringer Ingelheim Investigational Site

    Vista, California

  • 511.84.01029 Boehringer Ingelheim Investigational Site

    Walnut Creek, California

  • 511.84.01137 Boehringer Ingelheim Investigational Site

    Westlake Village, California

  • 511.84.01090 Boehringer Ingelheim Investigational Site

    Aurora, Colorado

  • 511.84.01164 Boehringer Ingelheim Investigational Site

    Denver, Colorado

  • 511.84.01184 Boehringer Ingelheim Investigational Site

    Denver, Colorado

  • 511.84.01004 Boehringer Ingelheim Investigational Site

    Englewood, Colorado

  • 511.84.01006 Boehringer Ingelheim Investigational Site

    Wheat Ridge, Colorado

  • 511.84.01138 Boehringer Ingelheim Investigational Site

    Farmington, Connecticut

  • 511.84.01044 Boehringer Ingelheim Investigational Site

    Groton, Connecticut

  • 511.84.01016 Boehringer Ingelheim Investigational Site

    Hartford, Connecticut

  • 511.84.01108 Boehringer Ingelheim Investigational Site

    New Britain, Connecticut

  • 511.84.01168 Boehringer Ingelheim Investigational Site

    New London, Connecticut

  • 511.84.01166 Boehringer Ingelheim Investigational Site

    Newark, Delaware

  • 511.84.01160 Boehringer Ingelheim Investigational Site

    Washington D.C., District of Columbia

  • 511.84.01065 Boehringer Ingelheim Investigational Site

    Aventura, Florida

Showing 40 of 196 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.